Clinical trials: Patient Care
Small Cell Lung Carcinoma (SCLC)
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer
This study is open to adults with extensive stage small cell lung cancer. The study is in people with advanced cancer that are eligible for standard of care including chemotherapy and anti-PD-L1 (Programmed Cell Death Ligand 1)…
- Trial name
- DAREONᵀᴹ-8 (NCT06077500)
- Testing
- BI 764532, Carboplatin, Etoposide
- Where
- 21 sites in United States, Belgium and 6 more
- Volunteers
- 46 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus
Evaluation of an Ascensia Diabetes Care Blood Glucose Meter and App System
The purpose of this study is to assess the utility of the Contour Diabetes App 2.0 when used with the Contour Next One meter (the Onyx system).
- Trial name
- NCT03165110
- Testing
- Onyx BG Meter / App System
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Ascensia Diabetes Care
Schizophrenia
A Long-Term, Open-Label, Study on Schizophrenia
The primary purpose of the study is to help answer the following research questions: How LY 2140023 can be tolerated by patients with Schizophrenia compared to standard of care treatment in 52 weeks time period.
- Trial name
- NCT01129674
- Testing
- LY2140023, Olanzapine, Aripiprazole
- Where
- 81 sites in United States, Croatia and 7 more
- Volunteers
- 560 people
- Sponsor
- Denovo Biopharma LLC
Diabetes, Diabetes Mellitus, Type 2
A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden
This trial is conducted in Europe. The aim of this study is to investigate a retrospective database assessment of clinical effectiveness in type 2 diabetes patients treated with liraglutide from primary care centers in Sweden.
- Trial name
- NCT02077946
- Testing
- liraglutide, sitagliptin
- Where
- Sweden
- Volunteers
- 1,059 people
- Sponsor
- Novo Nordisk A/S
Infection, Bacterial Infection
Procalcitonin Level to Discontinue Antibiotics on ICU Patients With no Obvious Site of Infection
The purpose of this study is to test whether a U.S. Food and Drug Administration (FDA) approved laboratory test (PCT Kryptor) can help doctors make better decisions on the need for antibiotic therapy in ICU patients with…
- Conditions
- Infection, Bacterial Infection, Sepsis
- Trial name
- NCT00407147
- Testing
- Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Brahms AG
Respiratory Insufficiency, Dyspnea
HVNI Ambulation Feasibility Study
The pilot/feasibility study evaluates the ability of High Velocity Nasal Insufflation (HVNI) therapy to facilitate ambulation and mobilization in patients experiencing shortness of breath, as compared to simple oxygen therapy.
- Trial name
- NCT03885726
- Testing
- Precision Flow Plus, Treatment as Usual
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Vapotherm, Inc.
Nasal Polyps
Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma
A Phase 3b Proof-of-Concept study to evaluate the ability of fevipiprant 150 mg and 450 mg, compared with placebo, as add-on to nasal spray standard-of-care (SoC), in reducing endoscopic nasal polyp score in adult (≥ 18 years)…
- Trial name
- THUNDER (NCT03681093)
- Testing
- Fevipiprant 150 mg, Fevipiprant 450 mg
- Where
- 25 sites in United States, Argentina and 7 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia, Acute Myelogenous Leukemia
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
This study will examine the safety profile of vadastuximab talirine (SGN-CD33A) by itself (monotherapy) or in combination with other standard treatments.
- Trial name
- NCT02326584
- Testing
- Standard dose cytarabine for induction, SGN-CD33A, Daunorubicin
- Where
- 13 sites in United States
- Volunteers
- 116 people
- Sponsor
- Seagen Inc.
Intracranial Aneurysms
CARE: A Prospective Multicenter Case Study to Assess Radiation Exposure in Patients Treated With the Penumbra Coil 400
The primary objective of this study is to gather data on the radiation exposure in patients treated with the Penumbra Coil 400™ System (PC 400) or conventional coils per their respective indications for use.This is a multicenter…
- Trial name
- CARE (NCT02122133)
- Testing
- PC 400
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Penumbra Inc.
Cachexia
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia.
- Trial name
- NCT05865535
- Testing
- AV-380
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Surgical Procedure, Unspecified
VRES Study in Two Phases to Monitor Cardiac Surgical Patients Following Discharge From ICU
Failure to recognise deterioration early is a major cause of preventable deaths amongst hospital patients. The investigators wish to study whether continuous monitoring of 'vital signs' (pulse rate, breathing rate, and blood…
- Trial name
- VRES (NCT02427828)
- Testing
- Visensia Respiration Rate Estimation Service (VRES)
- Where
- United Kingdom
- Volunteers
- 208 people
- Sponsor
- OBS Medical Ltd
Metastatic Pancreatic Cancer
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
To investigate the tolerability and safety of ONO-7913 and ONO-4538 used in combination with modified FOLFIRINOX (mFFX therapy), the standard of care, as first-line treatment in patients with metastatic pancreatic cancer.
- Trial name
- NCT06532344
- Testing
- ONO-7913, ONO-4538, Oxaliplatin
- Where
- 9 sites in Japan
- Volunteers
- 32 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Compliance, Patient
Explorative Clinical Study on the Performance and Acceptance of New Intermittent Catheters in Healthy Volunteers
Performance and acceptance of new intermittent catheters tested in healthy volunteers
- Trial name
- NCT04231149
- Testing
- Test product 2, Test product 3, Comparator
- Where
- Denmark
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Coloplast A/S
Palliative Care, Pain
A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy
The purpose of this study is to determine whether Sativex® and GW-2000-02 are effective in the management of subjects with intractable cancer-related pain.
- Conditions
- Palliative Care, Pain, Cancer
- Trial name
- SPRAY (NCT00674609)
- Testing
- Sativex®, THC Alone
- Where
- United Kingdom
- Volunteers
- 177 people
- Sponsor
- Jazz Pharmaceuticals
Neuroendocrine Tumors
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in…
- Trial name
- COMPOSE (NCT04919226)
- Testing
- 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 259 people
- Sponsor
- ITM Solucin GmbH
Colorectal Cancer
Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy
The purpose of this study is to investigate the safety and efficacy of the use of OCZ103-OS in combination with standard of care as a second line treatment in subjects with unresectable and locally recurrent or metastatic…
- Trial name
- NCT01378143
- Testing
- OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI
- Where
- 7 sites in Canada
- Volunteers
- 53 people
- Sponsor
- Oncozyme Pharma Inc.
Colorectal Neoplasms
MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer
The purpose of the study is to determine the feasibility of generating sufficient MicroOrganoSpheres (MOS) from a biopsy of a subject's adenocarcinoma of the colon and/or rectum that is metastatic to the liver and completing a…
- Trial name
- MODEL-CRC (NCT05189171)
- Testing
- MicroOrganoSphere (MOS) drug screen
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- Xilis, Inc.
Hepatocellular Carcinoma
A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
This study is an open phase II clinical study, which consists of part a and Part B. Part a will evaluate the safety and tolerability of absk-011 combined with atilizumab in patients with advanced or unresectable HCC to And pk/pd…
- Trial name
- NCT05441475
- Testing
- ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w, ABSK-011 200mg BID combined with atilizumab 1200 mg q3w and bevacizumab 15mg/kg, ABSK-011 200mg BID combined with toripalimab 240 mg and bevacizumab biosimilar 15 mg/kg
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Cardiac Pacing, Cardiac Pacemaker
BIO|STREAM.CSP Study
The registry is designed to assess outcome, performance and residual safety aspects of BIOTRONIK products which are used in the context of CSP based on long-term data from an unselected, real-life clinical set-up.
- Conditions
- Cardiac Pacing, Cardiac Pacemaker, Implantable Cardioverter Defibrillator, Cardiac Resynchronization Therapy Devices
- Trial name
- NCT07393009
- Testing
- Implantation of the Solia CSP S pacing lead for LBBAP
- Where
- 46 sites in Australia, Austria and 11 more
- Volunteers
- 1,000 people
- Sponsor
- Biotronik SE & Co. KG
Breast Cancer
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
This Phase 3 clinical study compares the efficacy and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at…
- Trial name
- EMERALD (NCT03778931)
- Testing
- Elacestrant, Standard of Care
- Where
- 244 sites in United States, Argentina and 15 more
- Volunteers
- 478 people
- Sponsor
- Stemline Therapeutics, Inc.